Biotech Takes Innovative Approach To Raising Capital For Its Promising Anti-Cancer Drug
Dr. Vuong Trieu, CEO & Chairman of Oncotelic Therapeutics, Inc. was recently a guest on Benzinga’s All-Access.
Oncotelic is a biotechnology company focused on developing RNA therapeutics for hard-to-treat cancers. The company has extensive experience in the field and its lead candidate OT-101 has shown very positive results in trials.